Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI vs. standard tool: which catches more drug dangers in the ICU?

NCT ID NCT07314125

Knowledge-focused Sponsor: Bursa Yuksek Ihtisas Training and Research Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether ChatGPT-5 can detect harmful drug interactions in intensive care patients better than a standard computer system. Researchers analyzed medication lists from 101 ICU patients and compared the AI's findings to the usual tool. The goal is to see if AI can improve safety for critically ill patients on multiple medications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

101 people

The number who actually took part.

Started

Sep 2025

Finished

Oct 2025

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of adult patients (≥18 years) admitted to the intensive care unit (ICU) for at least 48 hours at a tertiary care hospital. Eligible patients received four or more concurrent medications during their ICU stay, and only those with complete clinical and medication records were included. Patients with incomplete drug or interaction data, those receiving experimental or unproven drugs, as well as pediatric or pregnant patients, were excluded

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients aged 18 years or older * Admission to the intensive care unit (ICU) for at least 48 hours * Receipt of five or more medications concurrently during ICU stay * Availability of complete clinical data and medication lists Exclusion Criteria: * Cases with incomplete medication or interaction data * Patients receiving experimental or unproven drugs * Pediatric patients or those with pregnancy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Artifical intelligence are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Artifical intelligence

Contacts and locations

Locations

  • Bursa Yuksek Ihtisas Research and Education Hospital

    Bursa, Bursa, 16235, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.